Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well abiraterone acetate, prednisone, and apalutamide work in
treating patients with hormone-naive prostate cancer that has spread to other places in the
body. Androgen can cause the growth of prostate cancer cells. Antihormone therapy, such as
abiraterone acetate and apalutamide may lessen the amount of androgen made by the body.